BTN2A1: A Potential Drug Target for Muscle-Related Therapies

Target Name: BTN2A1

NCBI ID: G11120

BTN2A1

Other Name(s): Butyrophilin BTF1 | butyrophilin subfamily 2 member A1 | BK14H9.1 | Butyrophilin subfamily 2 member A1, transcript variant 1 | BTN2A1 variant 1 | Butyrophilin subfamily 2 member A1 (isoform 1) | BTF1 | DJ3E1.1 | Butyrophilin subfamily 2 member A1 | Butyrophilin, subfamily 2, member A1 | BT2.1 | FLJ36567 | BT2A1_HUMAN | BTN2.1

BTN2A1: A Potential Drug Target for Muscle-Related Therapies

BTN2A1, or Butyrophilin BTF1, is a protein that is expressed in high levels in muscle tissue and is known for its role in muscle function and development. It is a member of the BT family of proteins, which are involved in various physiological processes in the body, including muscle function and development. In this article, we will discuss the potential implications of BTN2A1 as a drug target or biomarker.

The BTN2A1 protein is composed of 254 amino acid residues and has a calculated molecular weight of 31.1 kDa. It is expressed in high levels in muscle tissue and is primarily localized to the sarcolemma of muscle cells, which is the outermost layer of muscle cells. BTN2A1 is involved in various physiological processes in muscle tissue, including muscle contraction and relaxation, force generation, and neurotransmitter release.

One of the key functions of BTN2A1 is its role in muscle contraction. During muscle contraction, BTN2A1 is involved in the regulation of the myosin ATPase, which is responsible for the production of ATP, the energy currency of the muscle. Myosin ATPase is a protein that is responsible for the rapid and forceful muscle contractions that are necessary for movement. BTN2A1 plays a critical role in regulating myosin ATPase activity, by interacting with its downstream target, the myosin regulatory protein (MyRP).

In addition to its role in muscle contraction, BTN2A1 is also involved in the regulation of muscle relaxation and force generation. During muscle relaxation, BTN2A1 is involved in the regulation of the myosin ATPase-associated protein (MyBap), which is responsible for the relaxation of muscle fibers. MyBap is a protein that is expressed in high levels in muscle tissue and is involved in the regulation of various physiological processes in muscle tissue, including muscle relaxation and force generation. BTN2A1 plays a critical role in regulating MyBap activity, by interacting with its downstream target, the myosin regulatory protein (MyRP).

BTN2A1 is also involved in the regulation of neurotransmitter release from muscle fibers. During muscle activity, BTN2A1 is involved in the regulation of the release of various neurotransmitters, including insulin, growth factor-1 (GF-1), and various ion channels. These neurotransmitters play important roles in muscle function and development, and BTN2A1 is involved in their regulation.

In conclusion, BTN2A1 is a protein that is involved in various physiological processes in muscle tissue, including muscle contraction, relaxation, and force generation. It is expressed in high levels in muscle tissue and plays a critical role in the regulation of myosin ATPase, MyBap, and neurotransmitter release from muscle fibers. As a drug target or biomarker, BTN2A1 has the potential to be a useful target for the development of muscle-related therapies.

Protein Name: Butyrophilin Subfamily 2 Member A1

The "BTN2A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BTN2A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets